Tags

Type your tag names separated by a space and hit enter

Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma.
J Thorac Oncol. 2013 Nov; 8(11):1371-7.JT

Abstract

INTRODUCTION

Fibroblast growth factor receptor 1 (FGFR1) gene amplification was recently reported as a recurrent abnormality in 10% to 20% of primary lung squamous cell carcinomas (SqCCs), and has attracted significant interest as a potential therapeutic target. Limited data are available for its prognostic impact in early-stage SqCC.

METHODS

Tissue microarrays containing 135 primary lung SqCCs and 58 matching lymph node metastases were tested by interphase fluorescence in situ hybridization for DNA copy number (CN) abnormalities at the 8p12 region including FGFR1.

RESULTS

FGFR1amplification was found in 18.2% (22 of 121 evaluable) of primary SqCC, using a definition of average copies of FGFR1 per cell of 5.0 or more. Concordance rate between primaries and matching lymph node metastases was 97.7% (43 of 44; 7 amplified and 37 nonamplified), with the only discordant case showing CN at approximately the dichotomous cutoff. Similarly, concordance between two separate lymph node metastases in each of 10 patients was 100% (1 amplified and 9 nonamplified). Using various CN cutoffs, we found no statistically significant association between FGFR1 CN abnormalities and patient age, sex, tumor grade, stage, smoking status, disease-free survival, cause-specific survival, or overall survival.

CONCLUSION

FGFR1 amplification is not prognostic in resected lung squamous cell carcinoma patients.

Authors+Show Affiliations

*Departments of Pathology, †Ontario Cancer Institute, ‡Department of Biostatistics, §Division of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; and ¶Departments of Laboratory Medicine and Pathobiology, ‖Medicine, University of Toronto, Ontario, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24077455

Citation

Craddock, Kenneth J., et al. "Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 8, no. 11, 2013, pp. 1371-7.
Craddock KJ, Ludkovski O, Sykes J, et al. Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J Thorac Oncol. 2013;8(11):1371-7.
Craddock, K. J., Ludkovski, O., Sykes, J., Shepherd, F. A., & Tsao, M. S. (2013). Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 8(11), 1371-7. https://doi.org/10.1097/JTO.0b013e3182a46fe9
Craddock KJ, et al. Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma. J Thorac Oncol. 2013;8(11):1371-7. PubMed PMID: 24077455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. AU - Craddock,Kenneth J, AU - Ludkovski,Olga, AU - Sykes,Jenna, AU - Shepherd,Frances A, AU - Tsao,Ming-Sound, PY - 2013/10/1/entrez PY - 2013/10/1/pubmed PY - 2014/5/23/medline SP - 1371 EP - 7 JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer JO - J Thorac Oncol VL - 8 IS - 11 N2 - INTRODUCTION: Fibroblast growth factor receptor 1 (FGFR1) gene amplification was recently reported as a recurrent abnormality in 10% to 20% of primary lung squamous cell carcinomas (SqCCs), and has attracted significant interest as a potential therapeutic target. Limited data are available for its prognostic impact in early-stage SqCC. METHODS: Tissue microarrays containing 135 primary lung SqCCs and 58 matching lymph node metastases were tested by interphase fluorescence in situ hybridization for DNA copy number (CN) abnormalities at the 8p12 region including FGFR1. RESULTS: FGFR1amplification was found in 18.2% (22 of 121 evaluable) of primary SqCC, using a definition of average copies of FGFR1 per cell of 5.0 or more. Concordance rate between primaries and matching lymph node metastases was 97.7% (43 of 44; 7 amplified and 37 nonamplified), with the only discordant case showing CN at approximately the dichotomous cutoff. Similarly, concordance between two separate lymph node metastases in each of 10 patients was 100% (1 amplified and 9 nonamplified). Using various CN cutoffs, we found no statistically significant association between FGFR1 CN abnormalities and patient age, sex, tumor grade, stage, smoking status, disease-free survival, cause-specific survival, or overall survival. CONCLUSION: FGFR1 amplification is not prognostic in resected lung squamous cell carcinoma patients. SN - 1556-1380 UR - https://www.unboundmedicine.com/medline/citation/24077455/Prognostic_value_of_fibroblast_growth_factor_receptor_1_gene_locus_amplification_in_resected_lung_squamous_cell_carcinoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(15)32167-5 DB - PRIME DP - Unbound Medicine ER -